Key Drivers
- Improving Margins
- Strong Liquidity
- Negative Equity
AIAI Summary
Guardant's investment case has shifted from proving demand to proving that Shield's expanding coverage can convert into profitable, cash-generative volume before pricing pressure, high operating spend, and the $245M+ patent exposure erode its balance-sheet cushion; investors should favor sustained evidence of lower Shield test costs and narrowing free-cash-flow burn over headline adoption alone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improving Margins
- •Strong Liquidity
- •Negative Equity
GH shows improving margins and strong liquidity, but persistent cash burn, negative equity, and a high 17.3x sales valuation keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Resistance test
- •Elevated volatility
GH's last-month uptrend remains constructive above $174–175 support, but its sharp run toward $183.10 resistance raises near-term pullback risk.
Sharp rise from about $157 to $183 indicates elevated volatility
Sentiment & News
Key News Insights:
- •Patent appeal
- •FDA expansion
- •Institutional buying
Guardant Health faces a major $245.2M patent-liability overhang despite an appeal stay, while FDA approvals, expanding test coverage, and new institutional buying support its longer-term growth outlook.
Near-term shares may remain pressured by litigation uncertainty, but commercial and regulatory progress could cushion longer-term sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings